JP2003524623A5 - - Google Patents

Download PDF

Info

Publication number
JP2003524623A5
JP2003524623A5 JP2000610472A JP2000610472A JP2003524623A5 JP 2003524623 A5 JP2003524623 A5 JP 2003524623A5 JP 2000610472 A JP2000610472 A JP 2000610472A JP 2000610472 A JP2000610472 A JP 2000610472A JP 2003524623 A5 JP2003524623 A5 JP 2003524623A5
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
hydrogen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000610472A
Other languages
Japanese (ja)
Other versions
JP2003524623A (en
JP2003524623A6 (en
JP4709392B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008404 external-priority patent/WO2000061139A1/en
Publication of JP2003524623A publication Critical patent/JP2003524623A/en
Publication of JP2003524623A6 publication Critical patent/JP2003524623A6/en
Publication of JP2003524623A5 publication Critical patent/JP2003524623A5/ja
Application granted granted Critical
Publication of JP4709392B2 publication Critical patent/JP4709392B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 式I:
【化1】

Figure 2003524623
式中:
XはCH2または酸素であり;
R1は水素またはアルキルであり;そして
R2、R3、R4及びR5は独立して水素またはアルキルであり、そしてXがCH2である場合には、R4及びR5はベンゼン環を形成するように連結されたアルケン基であることができ、そしてXが酸素である場合には、R2とR3及び/またはR4とR5は一緒に以下の式(II):
【化2】
Figure 2003524623
式中、
R6及びR7は同じまたは異なり、水素またはアルキルであり、そしてシクロペンチルまたはシクロヘキシル環を形成するように連結される、
のメチレンジオキシ基であることができる、
の化合物を有効成分として含んでなる哺乳類における血液グルコースレベルを下げるための製薬学的製剤
【請求項2】 式Iの化合物がトピラメートである請求項1記載の製剤
【請求項3】 式Iの化合物が約100〜400mg投与される請求項1記載の製剤。 [Claims]
  1. Formula I:
Embedded image
Figure 2003524623
  Where:
  X is CHTwoOr oxygen;
  R1Is hydrogen or alkyl; and
  RTwo, RThree, RFourAnd RFiveIs independently hydrogen or alkyl, and X is CHTwo, Then RFourAnd RFiveCan be an alkene group linked to form a benzene ring, and when X is oxygen, RTwoAnd RThreeAnd / or RFourAnd RFiveTogether with the following formula (II):
Embedded image
Figure 2003524623
  Where:
  R6And R7Are the same or different and are hydrogen or alkyl, and are linked to form a cyclopentyl or cyclohexyl ring,
Methylenedioxy group of
Compound ofComprising as an active ingredientDecrease blood glucose levels in mammalsPharmaceutical preparations for.
    2. The compound according to claim 1, wherein the compound of formula I is topiramate.The described formulation.
    (3) The compound of formula IAbout 100-400mg administrationBe doneClaim 1The described formulation.

JP2000610472A 1999-04-08 2000-03-30 Anticonvulsant derivatives useful for lowering blood glucose levels Expired - Lifetime JP4709392B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12839899P 1999-04-08 1999-04-08
US60/128,398 1999-04-08
US09/538,803 2000-03-30
PCT/US2000/008404 WO2000061139A1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in reducing blood glucose levels
US09/538,803 US6362220B1 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful in reducing blood glucose levels

Publications (4)

Publication Number Publication Date
JP2003524623A JP2003524623A (en) 2003-08-19
JP2003524623A6 JP2003524623A6 (en) 2006-12-14
JP2003524623A5 true JP2003524623A5 (en) 2007-02-15
JP4709392B2 JP4709392B2 (en) 2011-06-22

Family

ID=26826545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610472A Expired - Lifetime JP4709392B2 (en) 1999-04-08 2000-03-30 Anticonvulsant derivatives useful for lowering blood glucose levels

Country Status (1)

Country Link
JP (1) JP4709392B2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106193C (en) * 1996-06-28 2003-04-23 奥索·麦克尼尔药品公司 Anticonvulsant sulfamate derivs. useful in treating obesity

Similar Documents

Publication Publication Date Title
JP2003521471A5 (en)
JP2004505004A5 (en)
JP2002541199A5 (en)
ATE226815T1 (en) MANUFACTURING OF MEDICINAL PRODUCTS
JP2003501474A5 (en)
RU2003100076A (en) ANTI-CURRENT DERIVATIVES USED TO PREVENT DEVELOPMENT OF DIABETES AND SYNDROME X
CA2399208A1 (en) Nucleoside analogs with carboxamidine modified monocyclic base
Xiang et al. Transbuccal delivery of 2′, 3′-dideoxycytidine: in vitro permeation study and histological investigation
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EE04800B1 (en) Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
JP2003500442A5 (en)
JP2003506416A5 (en)
HUP0500558A2 (en) Low dose entecavir formulation and process for its preparation
DK0830145T3 (en) Formulations comprising leflunomide
JP2002519425A5 (en)
YU17700A (en) Oral copositions of levosimendan
KR970706792A (en) The lyophilizate of lipid complex of water insoluble camptothecins of water-insoluble camptothecin.
JP2002536328A5 (en)
RU97107856A (en) LIOPHYLIZATE OF THE LIPID COMPLEX OF WATER-INSOLVED CAMPOTECINE
KR890004701A (en) Antiretrovirus castanospermine ester
JP2004512362A (en) Oral self-emulsifying formulation of pyranone protease inhibitor
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch